Document is current

Article History

Received: 28 April 2025

Accepted: 23 May 2025

First Online: 11 June 2025

Declarations

:

: April W. Armstrong has served as a research investigator and/or consultant to AbbVie, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, Johnson & Johnson, KHK, Leo, Modernizing Medicine, Novartis, Ortho Dermatologics, Regeneron, Sanofi, Sun Pharma, and UCB. Steven R. Feldman has received research, speaking and/or consulting support from: AbbVie, Accordant, Almirall, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Caremark, Celgene, Dermavant, Eli Lilly, Eurofins, Forte, Galderma, GlaxoSmithKline/Stiefel, Helsinn, Informa, Johnson & Johnson, Leo Pharma, Menlo, Merck, Mylan, Novan, Novartis, Ortho Dermatology, Pfizer, Qurient, Regeneron, Samsung, Sanofi, Sun Pharma, Teladoc, the National Biological Corporation, the National Psoriasis Foundation, UCB, UpToDate, and vTv Therapeutics. He is founder and part owner of Causa Research and holds stock in Sensal Health. Steven R. Feldman is an Editorial Board member of Dermatology and Therapy. Steven R. Feldman was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Timothy Fitzgerald and Theodore Alkousakis are employees and shareholders of Johnson & Johnson. Adam Sima is an employee of CorEvitas, LLC, and a shareholder of Thermo Fisher Scientific. Hyung-Joo Kang is an employee of CorEvitas, LLC. Alvin Li is an employee of CorEvitas, LLC, and a stockholder of Eli Lilly. Sandra I. Main is a former employee of CorEvitas, LLC. She is currently an employee of the Health Plan of San Joaquin. Saakshi Khattri has received support for research from Bristol Myers Squibb, Celgene, LEO, Pfizer, and Takeda; as a speaker from AbbVie, Arcutis, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, LEO, Pfizer, Regeneron, Sanofi, and UCB; and as a consultant for AbbVie, Eli Lilly, Johnson & Johnson, Regeneron, Sanofi, and UCB. Linda Stein Gold is an investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.

: This study was performed in accordance with the Declaration of Helsinki and Guidelines for Good Pharmacoepidemiology Practice (GPP). All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review was obtained through a central institutional review board (IRB; Advarra, Protocol number is Pro00051221). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC, prior to the initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization prior to participating.